We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > cardiovascular risk

News List

Second-Line Antidiabetic Meds May Impact Cardiovascular Risk drugs
December 29, 2018
For adults with type 2 diabetes initiating second-line antidiabetic medications (ADM), cardiovascular risk is increased with use of sulfonylureas or basal insulin versus newer ADM classes.....
Novartis invests in Ionis’ therapies to reduce cardiovascular risk europeanpharmaceuticalreview
January 11, 2017
Novartis announced a collaboration and option agreement with Ionis Pharmaceuticals and its affiliate Akcea Therapeutics to license two novel treatments with the potential to significantly reduce cardiovascular risk in patients suffering from high levels o